Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One stock to keep an eye on is Takeda Pharmaceutical Co. (TAK). TAK is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A.

We should also highlight that TAK has a P/B ratio of 1.01. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 1.55. Over the past year, TAK's P/B has been as high as 1.07 and as low as 0.84, with a median of 0.98.

Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. TAK has a P/S ratio of 1.89. This compares to its industry's average P/S of 3.53.

Finally, investors will want to recognize that TAK has a P/CF ratio of 7.85. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 13.84. TAK's P/CF has been as high as 8.59 and as low as 5.84, with a median of 7.59, all within the past year.

Another great Medical - Drugs stock you could consider is USANA Health Sciences (USNA), which is a Zacks Rank of #1 (Strong Buy) stock with a Value Score of A.

USANA Health Sciences is currently trading with a Forward P/E ratio of 9.35 while its PEG ratio sits at 0.78. Both of the company's metrics compare favorably to its industry's average P/E of 45.93 and average PEG ratio of 2.00.

USNA's Forward P/E has been as high as 16.65 and as low as 7.83, with a median of 10.39. During the same time period, its PEG ratio has been as high as 1.39, as low as 0.65, with a median of 0.87.

Additionally, USANA Health Sciences has a P/B ratio of 1.04 while its industry's price-to-book ratio sits at 1.55. For USNA, this valuation metric has been as high as 1.49, as low as 0.83, with a median of 1.12 over the past year.

These are just a handful of the figures considered in Takeda Pharmaceutical Co. and USANA Health Sciences's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that TAK and USNA is an impressive value stock right now.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research